Moberg Pharma AB is a specialist pharmaceutical company dedicated to the commercialization of innovative drugs based on established substances. The company's primary focus is on bringing their flagship product, MOB-015, to the forefront of nail fungus treatment globally. Their plan entails obtaining the first market approval for MOB-015 in Europe by 2023.

Drawing from the success of their first-generation nail fungus product, Kerasal Nail®, Moberg Pharma aims to replicate their journey by combining direct sales in the U. S. The U.

S., EU, Japan, Canada, and China are identified as the most crucial markets, all benefiting from approved patent protection until 2032. Clinical Phase 3 studies involving over 800 patients have shown promising results, positioning MOB-015 as a potential future market leader in nail fungus treatment. Moberg Pharma has developed the product using their patented formulation technology, which enables the effective delivery of high concentrations of the proven antifungal agent terbinafine through the nail.

To facilitate global distribution, Moberg Pharma has secured five exclusive commercial partnerships, including Cipher Pharmaceuticals for Canada, Allderma in Scandinavia, Padagis in Israel, Dong-Koo Bio & Pharma Co., Ltd in South Korea, and Bayer AG for Europe. These partnerships enable the partners to market and sell MOB-015, while Moberg Pharma retains production and supply responsibility. The company aims to obtain market approval and initiate the launch of MOB-015 in 2023, with an estimated market potential of USD 250–500 million.

A significant portion of sales is anticipated to come from the high-priced U. S. With its dedication to innovation and strategic collaborations, Moberg Pharma is poised to revolutionize the nail fungus treatment landscape